All women received 5.7 mg iron / day through flour fortification during intervention and usual intermittent preventive
treatment against malaria.
Not exact matches
Novartis's global head of drug development and chief medical officer, Vas Narasimhan, has a piece up on Fortune exploring the strides that have been made in the fight
against malaria, including the development of an experimental Novartis
treatment called KAF156.
While the world has made incalculable gains in the struggle
against mosquito - borne diseases, new challenges — like resistance to artemisinin
treatments for
malaria — are now threatening to turn back the clock.
The World Health Organization (WHO) released a plan today to deal with a threat that could undermine the recent success in
malaria control: the emerging resistance
against artemisinin drugs, which are the cornerstone of
malaria treatment worldwide.
Medical researchers have developed a new
treatment against drug - resistant strains of the Plasmodium falciparum parasite that causes
malaria.
A subsidy program intended to drive down the cost of lifesaving
malaria drugs called artemisinin - based combination therapies — now considered the most effective
treatment against the parasitic disease — was unveiled today in Norway.
Artemisinins are a family of drugs that currently form the frontline
treatment against Plasmodium falciparum
malaria.
Conducting seminal intervention trials
against malaria that have fed directly into national and international policy which has contributed to the prevention of millions of deaths; these include trials of impregnated bed nets, the prevention of
malaria in pregnant women, interventions to improve community based
treatment and interventions to increase access to safe effective drugs.
In a huge boost to the global fight
against malaria, researchers have discovered how the
malaria parasite protects itself by building resistance
against the last - line in antimalarial medications, and how a new medical
treatment can overcome the parasite's defences.